Overexpression of OLIG2 and MYT1L Transcription Factors Enhance the Differentiation Potential of Human Mesenchymal Stem Cells into Oligodendrocytes

Background: Demyelinating diseases represent a broad spectrum of disorders and are characterized by the loss of specialized glial cells (oligodendrocytes), which eventually leads to neuronal degeneration. Stem cell-based regenerative approaches provide therapeutic options to regenerate demyelination-induced neurodegeneration. Objectives: The current study aims to explore the role of oligodendrocyte-specific transcription factors (OLIG2 and MYT1L) under suitable media composition to facilitate human umbilical-cord-derived mesenchymal stem cells (hUC-MSCs) differentiation toward oligodendrocyte for their potential use to treat demyelinating disorders. Methodology: hUC-MSCs were isolated, cultured, and characterized based on their morphological and phenotypic characteristics. hUC-MSCs were transfected with OLIG2 and MYT1L transcription factors individually and in synergistic (OLIG2 + MYT1L) groups using a lipofectamine-based transfection method and incubated under two different media compositions (normal and oligo induction media). Transfected hUC-MSCs were assessed for lineage specification and differentiation using qPCR. Differentiation was also analyzed via immunocytochemistry by determining the expression of oligodendrocyte-specific proteins. Results: All the transfected groups showed significant upregulation of GFAP and OLIG2 with downregulation of NES, demonstrating the MSC commitment toward the glial lineage. Transfected groups also presented significant overexpression of oligodendrocyte-specific markers (SOX10, NKX2.2, GALC, CNP, CSPG4, MBP, and PLP1). Immunocytochemical analysis showed intense expression of OLIG2, MYT1L, and NG2 proteins in both normal and oligo induction media after 3 and 7 days. Conclusions: The study concludes that OLIG2 and MYT1L have the potential to differentiate hUC-MSCs into oligodendrocyte-like cells, which is greatly facilitated by the oligo induction medium. The study may serve as a promising cell-based therapeutic strategy against demyelination-induced neuronal degeneration.

[1]  B. Bonetti,et al.  Extracellular Vesicles from Mesenchymal Stem Cells: Towards Novel Therapeutic Strategies for Neurodegenerative Diseases , 2023, International journal of molecular sciences.

[2]  D. S. Adli,et al.  Alpha terpineol directs bone marrow mesenchymal stem cells toward neuronal lineage through regulation of wnt signaling pathway , 2023, Cell biochemistry and function.

[3]  B. Lai,et al.  Expression of myelin transcription factor 1 and lamin B receptor mediate neural progenitor fate transition in the zebrafish spinal cord pMN domain , 2022, The Journal of biological chemistry.

[4]  Asma Alanazi,et al.  Mesenchymal stem cell therapy: A review of clinical trials for multiple sclerosis , 2022, Regenerative therapy.

[5]  S. Mojaverrostami,et al.  Combination effects of mesenchymal stem cells transplantation and anodal transcranial direct current stimulation on a cuprizone-induced mouse model of multiple sclerosis , 2022, Journal of Molecular Histology.

[6]  Hongda Li,et al.  The Oligodendrocyte Transcription Factor 2 OLIG2 regulates transcriptional repression during myelinogenesis in rodents , 2022, Nature communications.

[7]  Irfan Khan,et al.  Transcription regulators differentiate mesenchymal stem cells into chondroprogenitors, and their in vivo implantation regenerated the intervertebral disc degeneration , 2022, World journal of stem cells.

[8]  D. S. Adli,et al.  Effect of α-pinene and thymoquinone on the differentiation of bone marrow mesenchymal stem cells into neuroprogenitor cells , 2021, BioImpacts : BI.

[9]  W. Chung,et al.  MYT1L-associated neurodevelopmental disorder: description of 40 new cases and literature review of clinical and molecular aspects , 2021, Human Genetics.

[10]  R. Dale,et al.  Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody‐associated disease , 2021, Clinical & translational immunology.

[11]  Irfan Khan,et al.  Human umbilical cord-derived mesenchymal stem cells and their chondroprogenitor derivatives reduced pain and inflammation signaling and promote regeneration in a rat intervertebral disc degeneration model , 2021, Molecular and Cellular Biochemistry.

[12]  Irfan Khan,et al.  Umbilical cord-derived mesenchymal stem cells preconditioned with isorhamnetin: potential therapy for burn wounds , 2020, World journal of stem cells.

[13]  Soheila Madadi,et al.  The effect of microglial ablation and mesenchymal stem cell transplantation on a cuprizone‐induced demyelination model , 2020, Journal of cellular physiology.

[14]  K. Zibara,et al.  Mesenchymal Stem Cells Ameliorate Cuprizone-Induced Demyelination by Targeting Oxidative Stress and Mitochondrial Dysfunction , 2020, Cellular and Molecular Neurobiology.

[15]  V. Fineschi,et al.  Mesenchymal stem cells in neurodegenerative diseases: Opinion review on ethical dilemmas. , 2020, World journal of stem cells.

[16]  Md. Asiful Islam,et al.  Gene Therapy Approaches in an Autoimmune Demyelinating Disease: Multiple Sclerosis. , 2020, Current gene therapy.

[17]  S. Pollard,et al.  Reprogramming of Fibroblasts to Oligodendrocyte Progenitor-like Cells Using CRISPR/Cas9-Based Synthetic Transcription Factors , 2019, Stem cell reports.

[18]  Alonso Barrantes-Freer,et al.  Myelin in the Central Nervous System: Structure, Function, and Pathology. , 2019, Physiological reviews.

[19]  Lei Sun,et al.  Co-Transplantation of Human Umbilical Cord Mesenchymal Stem Cells and Human Neural Stem Cells Improves the Outcome in Rats with Spinal Cord Injury , 2019, Cell transplantation.

[20]  John H. Zhang,et al.  Transplanting Mesenchymal Stem Cells for Treatment of Ischemic Stroke , 2018, Cell transplantation.

[21]  Chao Zhao,et al.  Myt1L Promotes Differentiation of Oligodendrocyte Precursor Cells and is Necessary for Remyelination After Lysolecithin-Induced Demyelination , 2018, Neuroscience Bulletin.

[22]  A. Dulamea.  The contribution of oligodendrocytes and oligodendrocyte progenitor cells to central nervous system repair in multiple sclerosis: perspectives for remyelination therapeutic strategies , 2017, Neural regeneration research.

[23]  C. Simillion,et al.  Mesenchymal stromal cells from umbilical cord Wharton's jelly trigger oligodendroglial differentiation in neural progenitor cells through cell-to-cell contact. , 2017, Cytotherapy.

[24]  J. García-Verdugo,et al.  Intraventricular injections of mesenchymal stem cells activate endogenous functional remyelination in a chronic demyelinating murine model , 2016, Cell Death and Disease.

[25]  Irfan Khan,et al.  Promoting effect of small molecules in cardiomyogenic and neurogenic differentiation of rat bone marrow-derived mesenchymal stem cells , 2015, Drug design, development and therapy.

[26]  Carsten Lukas,et al.  Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model , 2015, Therapeutic advances in neurological disorders.

[27]  M. N. Bojnordi,et al.  Remyelination after Lysophosphatidyl Choline-Induced Demyelination Is Stimulated by Bone Marrow Stromal Cell-Derived Oligoprogenitor Cell Transplantation , 2014, Cells Tissues Organs.

[28]  S. Sadiq,et al.  Biomarkers of Therapeutic Response in Multiple Sclerosis: Current Status , 2014, Molecular Diagnosis & Therapy.

[29]  Jie Pan,et al.  Human umbilical cord stem cells ameliorate experimental autoimmune encephalomyelitis by regulating immunoinflammation and remyelination. , 2013, Stem cells and development.

[30]  C. Lucchinetti,et al.  Pathology of demyelinating diseases. , 2012, Annual review of pathology.

[31]  M. Chopp,et al.  Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice , 2005, Experimental Neurology.